Table 2 Potential savings of a reduction of the rate of decline in cognition as measured by MMSE in patients in the GERAS study with mild AD dementia
MMSE score change (baseline to 18 months) | % change in costs (95% CL) | ΔCosta (95% CL) | Difference in cost reduction |
|---|---|---|---|
Health care costs | |||
− 3.6 | 12.5% (6.7%; 18.3%) | £361 (194; 529) | NA |
− 2.52 (30% reduction) | 8.7% (4.7%; 12.8%) | £251 (136; 370) | £110 |
− 1.8 (50% reduction) | 6.2% (3.4%; 9.1%) | £179 (98; 263) | £182 |
Health care and social care costs | |||
− 3.6 | 13.1% (4.4%; 22.0%) | £1318 (443; 2214) | NA |
− 2.52 (30% reduction) | 9.2% (3.1%; 15.4%) | £926 (312; 1549) | £392 |
− 1.8 (50% reduction) | 6.5% (2.2%; 11.0%) | £654 (221; 1107) | £664 |
Total societal costs | |||
− 3.6 | 8.7% (1.8%; 15.7%) | £2239 (463; 4041) | NA |
− 2.52 (30% reduction) | 6.1% (1.2%; 11.0%) | £1570 (309; 2831) | £669 |
− 1.8 (50% reduction) | 4.3% (0.9%; 7.9%) | £1107 (232; 2033) | £1133 |